Literature DB >> 11304502

Diabetes, hypertension, and cardiovascular disease: an update.

J R Sowers1, M Epstein, E D Frohlich.   

Abstract

Cardiovascular diseases (CVDs) are the major causes of mortality in persons with diabetes, and many factors, including hypertension, contribute to this high prevalence of CVD. Hypertension is approximately twice as frequent in patients with diabetes compared with patients without the disease. Conversely, recent data suggest that hypertensive persons are more predisposed to the development of diabetes than are normotensive persons. Furthermore, up to 75% of CVD in diabetes may be attributable to hypertension, leading to recommendations for more aggressive treatment (ie, reducing blood pressure to <130/85 mm Hg) in persons with coexistent diabetes and hypertension. Other important risk factors for CVD in these patients include the following: obesity, atherosclerosis, dyslipidemia, microalbuminuria, endothelial dysfunction, platelet hyperaggregability, coagulation abnormalities, and "diabetic cardiomyopathy." The cardiomyopathy associated with diabetes is a unique myopathic state that appears to be independent of macrovascular/microvascular disease and contributes significantly to CVD morbidity and mortality in diabetic patients, especially those with coexistent hypertension. This update reviews the current knowledge regarding these risk factors and their treatment, with special emphasis on the cardiometabolic syndrome, hypertension, microalbuminuria, and diabetic cardiomyopathy. This update also examines the role of the renin-angiotensin system in the increased risk for CVD in diabetic patients and the impact of interrupting this system on the development of clinical diabetes as well as CVD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11304502     DOI: 10.1161/01.hyp.37.4.1053

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  326 in total

Review 1.  Treatment of coexisting diabetes and hypertension.

Authors:  N M Kaplan
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

Review 2.  The role of lifestyle change for prevention of cardiovascular disease in diabetes.

Authors:  Lisa R Staimez; Mary Beth Weber; Edward W Gregg
Journal:  Curr Atheroscler Rep       Date:  2014-12       Impact factor: 5.113

3.  Erythropoietin inhibits HIF-1α expression via upregulation of PHD-2 transcription and translation in an in vitro model of hypoxia-ischemia.

Authors:  Rhonda Souvenir; Jerry J Flores; Robert P Ostrowski; Anatol Manaenko; Kamil Duris; Jiping Tang
Journal:  Transl Stroke Res       Date:  2013-11-27       Impact factor: 6.829

Review 4.  Type 2 diabetes mellitus and hypertension: an update.

Authors:  Guido Lastra; Sofia Syed; L Romayne Kurukulasuriya; Camila Manrique; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

Review 5.  Challenges in vascular tissue engineering for diabetic patients.

Authors:  Jhilmil Dhulekar; Agneta Simionescu
Journal:  Acta Biomater       Date:  2018-02-01       Impact factor: 8.947

Review 6.  The use of ACE inhibitors on diabetic patients without renal disease.

Authors:  Dmitri Kirpichnikov; Nathaniel Winer; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

Review 7.  Cardiovascular risk factors in diabetic patients with hypertension.

Authors:  Nathaniel Winer; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 8.  Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction.

Authors:  George L Bakris; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 9.  Circadian changes in blood pressure and their relationships to the development of microalbuminuria in type 1 diabetic patients.

Authors:  Donn Hogan; Empar Lurbe; M Reza Salabat; Josep Redon; Daniel Batlle
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 10.  The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond.

Authors:  Kambiz Kalantarinia; Helmy M Siragy
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.